Company news

Q32 Bio Inc. news in 2025

Q32 Bio Inc.'s news releases, calls and decks from 2025, newest first.

View company

Q32 Bio Sells Complement Inhibitor ADX-097

December 1, 2025

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

October 21, 2025

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

August 28, 2025

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

June 25, 2025

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

April 30, 2025

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

April 16, 2025

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

March 11, 2025

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

March 8, 2025

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

February 28, 2025

Q32 Bio to Participate in Upcoming March Investor Conferences

February 26, 2025

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

February 9, 2025

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

February 3, 2025

Decks in 2025